|
1CQP
CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION
Deposited 1999-08-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–334(182 aa)
Fragment:I-DOMAIN, RESIDUES 153-334
|
Not recorded
|
MG MAGNESIUM ION × 1
803 LOVASTATIN × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;PEG 6000, HEPES, MAGNESIUM SULFATE, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.60 Å
R-free 0.257
|
|
1CQP
CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION
Deposited 1999-08-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–334(182 aa)
Fragment:I-DOMAIN, RESIDUES 153-334
|
Not recorded
|
MG MAGNESIUM ION × 1
803 LOVASTATIN × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;PEG 6000, HEPES, MAGNESIUM SULFATE, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.60 Å
R-free 0.257
|
|
1DGQ
NMR SOLUTION STRUCTURE OF THE INSERTED DOMAIN OF HUMAN LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1
Deposited 1999-11-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
149–336(188 aa)
Fragment:INSERTED DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7.2;295 K;Pressure AMBIENT
NMR measurement conditions
pH 7.3;295 K;Pressure AMBIENT
NMR sample composition
1.2 MM NMR SAMPLE OF PURIFIED AND UNIFORMLY 15N/13C ISOTOPICALLY LABELED LFA-1
I-DOMAIN
NMR sample composition
1.2 MM 15N UNIFORMLY LABELED SAMPLE WAS ALSO PREPARED IN THE FOLLOWING
CONDITIONS THAT WERE LESS AFFECTED BY LINE BROADENING
|
Resolution not provided
|
|
1LFA
CD11A I-DOMAIN WITH BOUND MN++
Deposited 1995-09-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
150–336(187 aa)
Chain B
150–336(187 aa)
|
Not recorded
|
MN MANGANESE (II) ION × 2
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.2;pH 5.2
|
Resolution 1.80 Å
R-free 0.251
|
|
1MJN
Crystal Structure of the intermediate affinity aL I domain mutant
Deposited 2002-08-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–331(179 aa)
Fragment:Intermediate Affinity aL I Domain
|
Mutation:L161C, F299C
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;298 K;PEG 4000, MgCl2, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.30 Å
R-free 0.202
|
|
1MQ8
Crystal structure of alphaL I domain in complex with ICAM-1
Deposited 2002-09-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
155–331(177 aa)
Fragment:Integrin alphaL I domain
|
Mutation:L186C, F324C
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;25% PEG 4000, 0.1 M sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP at 298K
|
Resolution 3.30 Å
R-free 0.313
|
|
1MQ8
Crystal structure of alphaL I domain in complex with ICAM-1
Deposited 2002-09-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
155–331(177 aa)
Fragment:Integrin alphaL I domain
|
Mutation:L186C, F324C
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;25% PEG 4000, 0.1 M sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP at 298K
|
Resolution 3.30 Å
R-free 0.313
|
|
1MQ9
Crystal structure of high affinity alphaL I domain with ligand mimetic crystal contact
Deposited 2002-09-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–331(179 aa)
Fragment:Integrin alphaL I domain
|
Mutation:K287C, K294C
|
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;20% PEG 2000 MME, 25 mM MnCl2, pH 7.0, VAPOR DIFFUSION, HANGING DROP at 298K
|
Resolution 2.00 Å
R-free 0.265
|
|
1MQA
Crystal structure of high affinity alphaL I domain in the absence of ligand or metal
Deposited 2002-09-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–331(179 aa)
Fragment:Integrin alphaL I domain
|
Mutation:K287C, K294C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;1.2 M ammonium phosphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP at 298K
|
Resolution 2.50 Å
R-free 0.283
|
|
1RD4
An allosteric inhibitor of LFA-1 bound to its I-domain
Deposited 2003-11-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
150–336(187 aa)
Fragment:I Domain, residues 125-311
|
Not recorded
|
L08 1-ACETYL-4-(4-{4-[(2-ETHOXYPHENYL)THIO]-3-NITROPHENYL}PYRIDIN-2-YL)PIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% (w/v) PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate, pH 4.6
|
Resolution 2.40 Å
R-free 0.290
|
|
1RD4
An allosteric inhibitor of LFA-1 bound to its I-domain
Deposited 2003-11-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
150–336(187 aa)
Fragment:I Domain, residues 125-311
|
Not recorded
|
L08 1-ACETYL-4-(4-{4-[(2-ETHOXYPHENYL)THIO]-3-NITROPHENYL}PYRIDIN-2-YL)PIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% (w/v) PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate, pH 4.6
|
Resolution 2.40 Å
R-free 0.290
|
|
1RD4
An allosteric inhibitor of LFA-1 bound to its I-domain
Deposited 2003-11-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
150–336(187 aa)
Fragment:I Domain, residues 125-311
|
Not recorded
|
L08 1-ACETYL-4-(4-{4-[(2-ETHOXYPHENYL)THIO]-3-NITROPHENYL}PYRIDIN-2-YL)PIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% (w/v) PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate, pH 4.6
|
Resolution 2.40 Å
R-free 0.290
|
|
1RD4
An allosteric inhibitor of LFA-1 bound to its I-domain
Deposited 2003-11-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain D
150–336(187 aa)
Fragment:I Domain, residues 125-311
|
Not recorded
|
L08 1-ACETYL-4-(4-{4-[(2-ETHOXYPHENYL)THIO]-3-NITROPHENYL}PYRIDIN-2-YL)PIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% (w/v) PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate, pH 4.6
|
Resolution 2.40 Å
R-free 0.290
|
|
1T0P
Structural Basis of ICAM recognition by integrin alpahLbeta2 revealed in the complex structure of binding domains of ICAM-3 and alphaLbeta2 at 1.65 A
Deposited 2004-04-12
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
153–326(174 aa)
Fragment:I domain
|
Not recorded
|
MG MAGNESIUM ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;298 K;PEG MME 5000, (NH4)2SO4, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.66 Å
R-free 0.241
|
|
1XDD
X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution
Deposited 2004-09-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
152–336(185 aa)
Fragment:I-domain
|
Not recorded
|
MG MAGNESIUM ION × 1
AAY 8-[2-((2S)-4-HYDROXY-1-{[5-(HYDROXYMETHYL)-6-METHOXY-2-NAPHTHYL]METHYL}-6-OXOPIPERIDIN-2-YL)ETHYL]-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2-METHYLBUTANOATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;293 K;ammonium acetate, sodium acetate, glycerol, PEG4000, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.206
|
|
1XDD
X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution
Deposited 2004-09-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
152–336(185 aa)
Fragment:I-domain
|
Not recorded
|
MG MAGNESIUM ION × 1
AAY 8-[2-((2S)-4-HYDROXY-1-{[5-(HYDROXYMETHYL)-6-METHOXY-2-NAPHTHYL]METHYL}-6-OXOPIPERIDIN-2-YL)ETHYL]-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2-METHYLBUTANOATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;293 K;ammonium acetate, sodium acetate, glycerol, PEG4000, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.206
|
|
1XDG
X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution
Deposited 2004-09-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
152–336(185 aa)
Fragment:I-domain
|
Not recorded
|
MG MAGNESIUM ION × 1
AB8 (1S,3R,8AS)-8-(2-{(4S,6S)-3-(4-HYDROXY-3-METHOXYBENZYL)-4-[2-(METHYLAMINO)-2-OXOETHYL]-2-OXO-1,3-OXAZINAN-6-YL}ETHYL)-3 ,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL (2R)-2-METHYLBUTANOATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;sodium citrate, ammonium acetate, glycerol, PEG4000, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.213
|
|
1XDG
X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution
Deposited 2004-09-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
152–336(185 aa)
Fragment:I-domain
|
Not recorded
|
MG MAGNESIUM ION × 1
AB8 (1S,3R,8AS)-8-(2-{(4S,6S)-3-(4-HYDROXY-3-METHOXYBENZYL)-4-[2-(METHYLAMINO)-2-OXOETHYL]-2-OXO-1,3-OXAZINAN-6-YL}ETHYL)-3 ,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL (2R)-2-METHYLBUTANOATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;sodium citrate, ammonium acetate, glycerol, PEG4000, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.213
|
|
1XUO
X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution
Deposited 2004-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
152–336(185 aa)
Fragment:I-domain
|
Not recorded
|
MG MAGNESIUM ION × 1
LA1 (2R)-2-[3-ISOBUTYL-2,5-DIOXO-4-(QUINOLIN-3-YLMETHYL)-1,4-DIAZEPAN-1-YL]-N-METHYL-3-(2-NAPHTHYL)PROPANAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;PEG 6000, HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.214
|
|
1XUO
X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution
Deposited 2004-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
152–336(185 aa)
Fragment:I-domain
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;PEG 6000, HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å
R-free 0.214
|
|
1ZON
CD11A I-DOMAIN WITHOUT BOUND CATION
Deposited 1996-06-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
150–336(187 aa)
Fragment:I-DOMAIN FRAGMENT OF LFA-1
|
Mutation:W189R, MIGHT BE ISOFORM
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8;pH 8.0
|
Resolution 2.00 Å
R-free 0.243
|
|
1ZOO
CD11A I-DOMAIN WITH BOUND MAGNESIUM ION
Deposited 1996-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
150–336(187 aa)
Fragment:I-DOMAIN FRAGMENT OF LFA-1
Chain B
150–336(187 aa)
Fragment:I-DOMAIN FRAGMENT OF LFA-1
|
Mutation:W189R, MIGHT BE ISOFORM
Mutation:W189R, MIGHT BE ISOFORM
|
MG MAGNESIUM ION × 2
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.2;pH 5.2
|
Resolution 3.00 Å
R-free 0.264
|
|
1ZOP
CD11A I-DOMAIN WITH BOUND MAGNESIUM ION
Deposited 1996-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
150–336(187 aa)
Chain B
150–336(187 aa)
|
Mutation:W189R, MIGHT BE ISOFORM
Mutation:W189R, MIGHT BE ISOFORM
|
MN MANGANESE (II) ION × 2
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.2;pH 5.2
|
Resolution 2.00 Å
R-free 0.263
|
|
2ICA
CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid
Deposited 2006-09-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
154–332(179 aa)
Fragment:VWFA domain, residues 154-332
|
Not recorded
|
2IC 5-[(5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7-TRIAZASPIRO [4.4]NON-7-YL]METHYL]-3-THIOPHENECARBOXYLICACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9;293 K;80% (w/v) sodium citrate, 5% (v/v) glycerol, measured pH 8.9, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.56 Å
R-free 0.223
|
|
2K8O
Solution structure of integrin Alpha L
Deposited 2008-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1113–1170(58 aa)
Fragment:Cytoplasmic
|
Mutation:M14I
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.2;298 K
NMR sample composition
0.5 mM [U-15N;U-13C] aL, % NaCl, % TCEP, % Phosphate buffer, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2M3E
The Integrin Alpha L Transmembrane Domain in Bicelles: Structure and Interaction with Integrin Beta 2
Deposited 2013-01-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1082–1128(47 aa)
Fragment:Transmembrane Domain
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;303 K;Ionic strength (raw mmCIF value) 50;Pressure ambient
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] integrin aL TM domain, 50 mM potassium phosphate, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided
|
|
2O7N
CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile
Deposited 2006-12-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
154–332(179 aa)
Fragment:VWFA DOMAIN, RESIDUES 154-332
|
Not recorded
|
2O7 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.9;293 K;78% (W/V) SODIUM CITRATE, 3% (V/V) ETHYLENE GLYCOL, 0.1 M SODIUM CITRATE, PH 5.6 (FINAL PH 8.9), VAPOR DIFFUSION, HANGING DROP, temperature 293K, pH 8.90
|
Resolution 1.75 Å
R-free 0.234
|
|
3BN3
crystal structure of ICAM-5 in complex with aL I domain
Deposited 2007-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
154–332(179 aa)
Fragment:I domain
|
Mutation:F265S, F292G
|
MG MAGNESIUM ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;296 K;0.1M HEPES pH7.5, 7.5%PEG8000, 10%glycerol, 5mM magnesium chloride, VAPOR DIFFUSION, HANGING DROP, temperature 296K
|
Resolution 2.10 Å
R-free 0.235
|
|
3BQM
LFA-1 I domain bound to inhibitors
Deposited 2007-12-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–334(182 aa)
Fragment:VWFA domain
|
Not recorded
|
BQM 3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;273 K;5% Peg400, 20% Peg3350, 50mM K2HPO4 pH 4.5, 10mM MgCl, 1mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 273K
|
Resolution 1.95 Å
R-free 0.284
|
|
3BQM
LFA-1 I domain bound to inhibitors
Deposited 2007-12-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
153–334(182 aa)
Fragment:VWFA domain
|
Not recorded
|
BQM 3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;273 K;5% Peg400, 20% Peg3350, 50mM K2HPO4 pH 4.5, 10mM MgCl, 1mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 273K
|
Resolution 1.95 Å
R-free 0.284
|
|
3BQM
LFA-1 I domain bound to inhibitors
Deposited 2007-12-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain B
153–334(182 aa)
Fragment:VWFA domain
Chain C
153–334(182 aa)
Fragment:VWFA domain
|
Not recorded
|
BQM 3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;273 K;5% Peg400, 20% Peg3350, 50mM K2HPO4 pH 4.5, 10mM MgCl, 1mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 273K
|
Resolution 1.95 Å
R-free 0.284
|
|
3BQN
LFA-1 I domain bound to inhibitors
Deposited 2007-12-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–334(182 aa)
Fragment:VWFA DOMAIN
|
Not recorded
|
BQN 4-{(2E)-3-[4-{[2-(pyridin-3-ylmethoxy)phenyl]sulfanyl}-2,3-bis(trifluoromethyl)phenyl]prop-2-enoyl}morpholine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;298 K;5% Peg400, 20% Peg3350, 50mM K2HPO4 pH 4.5, 10mM MgCl2, 1mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.252
|
|
3BQN
LFA-1 I domain bound to inhibitors
Deposited 2007-12-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
153–334(182 aa)
Fragment:VWFA DOMAIN
|
Not recorded
|
BQN 4-{(2E)-3-[4-{[2-(pyridin-3-ylmethoxy)phenyl]sulfanyl}-2,3-bis(trifluoromethyl)phenyl]prop-2-enoyl}morpholine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;298 K;5% Peg400, 20% Peg3350, 50mM K2HPO4 pH 4.5, 10mM MgCl2, 1mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.252
|
|
3BQN
LFA-1 I domain bound to inhibitors
Deposited 2007-12-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain B
153–334(182 aa)
Fragment:VWFA DOMAIN
Chain C
153–334(182 aa)
Fragment:VWFA DOMAIN
|
Not recorded
|
BQN 4-{(2E)-3-[4-{[2-(pyridin-3-ylmethoxy)phenyl]sulfanyl}-2,3-bis(trifluoromethyl)phenyl]prop-2-enoyl}morpholine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;298 K;5% Peg400, 20% Peg3350, 50mM K2HPO4 pH 4.5, 10mM MgCl2, 1mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.252
|
|
3E2M
LFA-1 I domain bound to inhibitors
Deposited 2008-08-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
152–334(183 aa)
Fragment:VWFA DOMAIN
Chain B
152–334(183 aa)
Fragment:VWFA DOMAIN
|
Not recorded
|
E2M cis-4-{[2-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)phenoxy]methyl}cyclohexanecarboxylic acid × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5;5% PEG400, 20% PEG3350, 50MM K2HPO4 PH 4.5, 10MM MGCL2, 1MM INHIBITOR, pH 4.50, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.00 Å
R-free 0.287
|
|
3E2M
LFA-1 I domain bound to inhibitors
Deposited 2008-08-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
152–334(183 aa)
Fragment:VWFA DOMAIN
|
Not recorded
|
E2M cis-4-{[2-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)phenoxy]methyl}cyclohexanecarboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5;5% PEG400, 20% PEG3350, 50MM K2HPO4 PH 4.5, 10MM MGCL2, 1MM INHIBITOR, pH 4.50, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.00 Å
R-free 0.287
|
|
3E2M
LFA-1 I domain bound to inhibitors
Deposited 2008-08-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
152–334(183 aa)
Fragment:VWFA DOMAIN
|
Not recorded
|
E2M cis-4-{[2-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)phenoxy]methyl}cyclohexanecarboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5;5% PEG400, 20% PEG3350, 50MM K2HPO4 PH 4.5, 10MM MGCL2, 1MM INHIBITOR, pH 4.50, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.00 Å
R-free 0.287
|
|
3EOA
Crystal structure the Fab fragment of Efalizumab in complex with LFA-1 I domain, Form I
Deposited 2008-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain I
153–333(181 aa)
Fragment:I domain
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.3;277 K;0.1M sodium citric, 0.2M sodium potassium tartrate, 1.6M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.264
|
|
3EOA
Crystal structure the Fab fragment of Efalizumab in complex with LFA-1 I domain, Form I
Deposited 2008-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain J
153–333(181 aa)
Fragment:I domain
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.3;277 K;0.1M sodium citric, 0.2M sodium potassium tartrate, 1.6M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.264
|
|
3EOB
Crystal structure the Fab fragment of Efalizumab in complex with LFA-1 I domain, Form II
Deposited 2008-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain I
153–333(181 aa)
Fragment:I domain
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.3;277 K;0.1M sodium cacodylate, 0.2M zinc acetate, 11% w/v PEG 8000, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.60 Å
R-free 0.333
|
|
3EOB
Crystal structure the Fab fragment of Efalizumab in complex with LFA-1 I domain, Form II
Deposited 2008-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain J
153–333(181 aa)
Fragment:I domain
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.3;277 K;0.1M sodium cacodylate, 0.2M zinc acetate, 11% w/v PEG 8000, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.60 Å
R-free 0.333
|
|
3F74
Crystal structure of wild type LFA1 I domain
Deposited 2008-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–332(180 aa)
Fragment:UNP residues 153-332, VWFA domain, I domain
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;295 K;o.1M sodium acetate, pH7.5, 0.2M ammonium acetate, 25% PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.70 Å
R-free 0.178
|
|
3F74
Crystal structure of wild type LFA1 I domain
Deposited 2008-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–332(180 aa)
Fragment:UNP residues 153-332, VWFA domain, I domain
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;295 K;o.1M sodium acetate, pH7.5, 0.2M ammonium acetate, 25% PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.70 Å
R-free 0.178
|
|
3F74
Crystal structure of wild type LFA1 I domain
Deposited 2008-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
153–332(180 aa)
Fragment:UNP residues 153-332, VWFA domain, I domain
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;295 K;o.1M sodium acetate, pH7.5, 0.2M ammonium acetate, 25% PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.70 Å
R-free 0.178
|
|
3F78
Crystal structure of wild type LFA1 I domain complexed with isoflurane
Deposited 2008-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–332(180 aa)
Fragment:UNP residues 153-332, VWFA domain, I domain
|
Not recorded
|
ICF 1-CHLORO-2,2,2-TRIFLUOROETHYL DIFLUOROMETHYL ETHER × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;295 K;0.1M sodium acetate pH7.5, 0.2M ammonium acetate, 25% PEG3350, 10mM isoflurane, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.60 Å
R-free 0.181
|
|
3F78
Crystal structure of wild type LFA1 I domain complexed with isoflurane
Deposited 2008-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–332(180 aa)
Fragment:UNP residues 153-332, VWFA domain, I domain
|
Not recorded
|
ICF 1-CHLORO-2,2,2-TRIFLUOROETHYL DIFLUOROMETHYL ETHER × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;295 K;0.1M sodium acetate pH7.5, 0.2M ammonium acetate, 25% PEG3350, 10mM isoflurane, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.60 Å
R-free 0.181
|
|
3F78
Crystal structure of wild type LFA1 I domain complexed with isoflurane
Deposited 2008-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
153–332(180 aa)
Fragment:UNP residues 153-332, VWFA domain, I domain
|
Not recorded
|
GOL GLYCEROL × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;295 K;0.1M sodium acetate pH7.5, 0.2M ammonium acetate, 25% PEG3350, 10mM isoflurane, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.60 Å
R-free 0.181
|
|
3HI6
Crystal structure of intermediate affinity I domain of integrin LFA-1 with the Fab fragment of its antibody AL-57
Deposited 2009-05-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
153–332(180 aa)
Fragment:UNP residues 153-332
|
Mutation:L186C, F324C
|
MN MANGANESE (II) ION × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;2M (NH4)2SO4, 0.1M NaAc, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å
R-free 0.226
|
|
3HI6
Crystal structure of intermediate affinity I domain of integrin LFA-1 with the Fab fragment of its antibody AL-57
Deposited 2009-05-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
153–332(180 aa)
Fragment:UNP residues 153-332
|
Mutation:L186C, F324C
|
MN MANGANESE (II) ION × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;2M (NH4)2SO4, 0.1M NaAc, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å
R-free 0.226
|
|
3HI6
Crystal structure of intermediate affinity I domain of integrin LFA-1 with the Fab fragment of its antibody AL-57
Deposited 2009-05-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 6
PDB declaration: hexameric
|
Chain A
153–332(180 aa)
Fragment:UNP residues 153-332
Chain B
153–332(180 aa)
Fragment:UNP residues 153-332
|
Mutation:L186C, F324C
Mutation:L186C, F324C
|
MN MANGANESE (II) ION × 2
SO4 SULFATE ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;2M (NH4)2SO4, 0.1M NaAc, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å
R-free 0.226
|
|
3M6F
CD11A I-domain complexed with 6-((5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7- TRIAZASPIRO[4.4]NON-7-YL)NICOTINIC ACID
Deposited 2010-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
154–332(179 aa)
Fragment:UNP residues 154-332
|
Not recorded
|
BJZ 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]pyridine-3-carboxylic acid × 1
NO3 NITRATE ION × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.85 Å
R-free 0.227
|
|
4IXD
X-ray structure of lfa-1 i-domain in complex with ibe-667 at 1.8a resolution
Deposited 2013-01-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
152–336(185 aa)
Fragment:I-DOMAIN, UNP residues 152-336
|
Not recorded
|
MG MAGNESIUM ION × 1
1HV 4-(3-{4-[(3-aminopropyl)carbamoyl]phenyl}-1H-indazol-1-yl)-N-methylbenzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 4.6;293 K;0.085M sodium acetate, pH4.6, 0.17M ammonium acetate, 15% glycerol and 25.5% (w/v) PEG4000 , VAPOR DIFFUSION, temperature 293.0K
|
Resolution 1.80 Å
R-free 0.199
|
|
4IXD
X-ray structure of lfa-1 i-domain in complex with ibe-667 at 1.8a resolution
Deposited 2013-01-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
152–336(185 aa)
Fragment:I-DOMAIN, UNP residues 152-336
|
Not recorded
|
MG MAGNESIUM ION × 2
1HV 4-(3-{4-[(3-aminopropyl)carbamoyl]phenyl}-1H-indazol-1-yl)-N-methylbenzamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 4.6;293 K;0.085M sodium acetate, pH4.6, 0.17M ammonium acetate, 15% glycerol and 25.5% (w/v) PEG4000 , VAPOR DIFFUSION, temperature 293.0K
|
Resolution 1.80 Å
R-free 0.199
|
|
5E6R
Structures of leukocyte integrin aLb2: The aI domain, the headpiece, and the pocket for the internal ligand
Deposited 2015-10-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–770(745 aa)
Fragment:UNP residues 26-615
|
Not recorded
|
MG MAGNESIUM ION × 1
CA CALCIUM ION × 4
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;0.1 M MES pH 6.5, 15% PEG 3350
|
Resolution 2.90 Å
R-free 0.229
|
|
5E6S
Structures of leukocyte integrin aLB2: The aI domain, the headpiece, and the pocket for the internal ligand
Deposited 2015-10-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–770(745 aa)
Fragment:UNP residues 26-770
|
Not recorded
|
MG MAGNESIUM ION × 1
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4;277 K;0.1 M Tris, pH 8, 0.1 M NaCl, and 8% polyethylene glycol (PEG) 20,000
|
Resolution 2.15 Å
R-free 0.234
|
|
5E6S
Structures of leukocyte integrin aLB2: The aI domain, the headpiece, and the pocket for the internal ligand
Deposited 2015-10-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
26–770(745 aa)
Fragment:UNP residues 26-770
|
Not recorded
|
MG MAGNESIUM ION × 1
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4;277 K;0.1 M Tris, pH 8, 0.1 M NaCl, and 8% polyethylene glycol (PEG) 20,000
|
Resolution 2.15 Å
R-free 0.234
|
|
5E6S
Structures of leukocyte integrin aLB2: The aI domain, the headpiece, and the pocket for the internal ligand
Deposited 2015-10-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
26–770(745 aa)
Fragment:UNP residues 26-770
|
Not recorded
|
MG MAGNESIUM ION × 1
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4;277 K;0.1 M Tris, pH 8, 0.1 M NaCl, and 8% polyethylene glycol (PEG) 20,000
|
Resolution 2.15 Å
R-free 0.234
|
|
5E6S
Structures of leukocyte integrin aLB2: The aI domain, the headpiece, and the pocket for the internal ligand
Deposited 2015-10-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer;Protein × 6
PDB declaration: hexameric
|
Chain A
26–770(745 aa)
Fragment:UNP residues 26-770
Chain C
26–770(745 aa)
Fragment:UNP residues 26-770
Chain E
26–770(745 aa)
Fragment:UNP residues 26-770
|
Not recorded
|
MG MAGNESIUM ION × 3
CA CALCIUM ION × 15
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4;277 K;0.1 M Tris, pH 8, 0.1 M NaCl, and 8% polyethylene glycol (PEG) 20,000
|
Resolution 2.15 Å
R-free 0.234
|
|
5E6U
Structures of leukocyte integrin aLb2: The aI domain, the headpiece, and the pocket for the internal ligand
Deposited 2015-10-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–770(745 aa)
Fragment:UNP residues 26-770
|
Not recorded
|
MG MAGNESIUM ION × 2
CA CALCIUM ION × 4
CL CHLORIDE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;0.1 M Mg-formate dehydrate and 15% PEG 3350
|
Resolution 2.50 Å
R-free 0.226
|
|
6BXB
Crystal structure of an extended b3 integrin P33
Deposited 2017-12-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–329(177 aa)
|
Not recorded
|
CA CALCIUM ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;20% PEG 6000, 0.1 M Tris-HCl (pH 8.5)
|
Resolution 2.39 Å
R-free 0.268
|
|
6BXB
Crystal structure of an extended b3 integrin P33
Deposited 2017-12-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–329(177 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;20% PEG 6000, 0.1 M Tris-HCl (pH 8.5)
|
Resolution 2.39 Å
R-free 0.268
|
|
6BXF
Crystal structure of an extended b3 integrin L33
Deposited 2017-12-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–329(177 aa)
|
Not recorded
|
GOL GLYCEROL × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;12% PEG 8000, 0.2 M NaCl, 0.1 M HEPES (pH 7.5)
|
Resolution 3.20 Å
R-free 0.335
|
|
6BXF
Crystal structure of an extended b3 integrin L33
Deposited 2017-12-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–329(177 aa)
|
Not recorded
|
GOL GLYCEROL × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;12% PEG 8000, 0.2 M NaCl, 0.1 M HEPES (pH 7.5)
|
Resolution 3.20 Å
R-free 0.335
|
|
6BXJ
Structure of a single-chain beta3 integrin
Deposited 2017-12-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–329(177 aa)
|
Not recorded
|
MG MAGNESIUM ION × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;10% PEG 8000, 20% 1,5-pentanediol, 4 mM alkalis, 66 mM Gly-Gly, 33 mM AMPD, pH 8.5.
|
Resolution 2.09 Å
R-free 0.234
|
|
6CKB
Crystal structure of an extended beta3 integrin P33
Deposited 2018-02-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–329(177 aa)
|
Not recorded
|
MG MAGNESIUM ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;277 K;20% PEG 6000, 0.1 M Tris-HCl (pH 8.5)
|
Resolution 2.80 Å
R-free 0.296
|
|
6CKB
Crystal structure of an extended beta3 integrin P33
Deposited 2018-02-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
153–329(177 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;277 K;20% PEG 6000, 0.1 M Tris-HCl (pH 8.5)
|
Resolution 2.80 Å
R-free 0.296
|
|
7KC3
X-ray structure of Lfa-1 I domain collected at 273 K
Deposited 2020-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
149–341(193 aa)
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;295 K;30% (w/v) PEG 3350 and 0.1 M potassium phosphate dibasic
|
Resolution 1.80 Å
R-free 0.212
|
|
7KC5
X-ray structure of Lfa-1 I domain in complex with BMS-68852 collected at 273 K
Deposited 2020-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–334(182 aa)
|
Not recorded
|
MG MAGNESIUM ION × 1
BJZ 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]pyridine-3-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;50 mM Tris pH 8.5, 10 mM MgSO4, 1 mM TCEP and 1 mM BMS-68852
|
Resolution 1.86 Å
R-free 0.216
|
|
7KC5
X-ray structure of Lfa-1 I domain in complex with BMS-68852 collected at 273 K
Deposited 2020-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
153–334(182 aa)
|
Not recorded
|
MG MAGNESIUM ION × 1
BJZ 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]pyridine-3-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;50 mM Tris pH 8.5, 10 mM MgSO4, 1 mM TCEP and 1 mM BMS-68852
|
Resolution 1.86 Å
R-free 0.216
|
|
7KC6
X-ray structure of Lfa-1 I domain in complex with Lovastatin collected at 273 K
Deposited 2020-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
153–334(182 aa)
|
Not recorded
|
803 LOVASTATIN × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M NH4NO3 and 20%(w/v) PEG 3350
|
Resolution 1.85 Å
R-free 0.225
|
|
7KC6
X-ray structure of Lfa-1 I domain in complex with Lovastatin collected at 273 K
Deposited 2020-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
153–334(182 aa)
|
Not recorded
|
803 LOVASTATIN × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M NH4NO3 and 20%(w/v) PEG 3350
|
Resolution 1.85 Å
R-free 0.225
|